

## p53 (phospho Ser6) Polyclonal Antibody

Catalog No: YP0210

**Reactivity:** Human; Monkey

**Applications:** WB;IHC;IF;IP;ELISA

Target: p53

**Fields:** >>Endocrine resistance;>>Platinum drug resistance;>>MAPK signaling

pathway;>>Sphingolipid signaling pathway;>>Cell cycle;>>p53 signaling

pathway;>>Mitophagy - animal;>>PI3K-Akt signaling

pathway;>>Apoptosis;>>Longevity regulating pathway;>>Ferroptosis;>>Cellular

senescence;>>Wnt signaling pathway;>>Neurotrophin signaling pathway;>>Thyroid hormone signaling pathway;>>Parkinson

disease;>>Amyotrophic lateral sclerosis;>>Huntington

disease;>>Shigellosis;>>Hepatitis C;>>Hepatitis B;>>Measles;>>Human cytomegalovirus infection;>>Human papillomavirus infection;>>Human T-cell

leukemia virus 1 infection;>>Kaposi sarcoma-associated herpesvirus infection;>>Herpes simplex virus 1 infection;>>Epstein-Barr virus

infection;>>Pathways in cancer;>>Transcriptional misregulation in cancer;>>Viral carcinogenesis;>>Proteoglycans in cancer;>>MicroRNAs in cancer;>>Colorectal cancer;>>Pancreatic cancer;>>Endometrial cancer;>>Glioma;>>Prostate

cancer;>>Thyroid cancer;>>Basal cell carcinoma;>>Melanoma;>>Bladder

Gene Name: TP53

**Protein Name:** Cellular tumor antigen p53

**Human Gene Id:** 7157

**Human Swiss Prot** P04637

No:

Mouse Swiss Prot P02340

No:

**Immunogen:** The antiserum was produced against synthesized peptide derived from human

p53 around the phosphorylation site of Ser6. AA range:1-50

**Specificity:** Phospho-p53 (S6) Polyclonal Antibody detects endogenous levels of p53 protein

only when phosphorylated at S6.



**Formulation:** Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source : Polyclonal, Rabbit, IgG

**Dilution:** WB 1:500 - 1:2000. IHC 1:100 - 1:300. Immunoprecipitation: 2-5 ug:mg lysate.

ELISA: 1:10000.. IF 1:50-200

**Purification:** The antibody was affinity-purified from rabbit antiserum by affinity-

chromatography using epitope-specific immunogen.

Concentration: 1 mg/ml

Storage Stability: -15°C to -25°C/1 year(Do not lower than -25°C)

Observed Band: 47kD

**Cell Pathway :** Stem cell pathway; WNT; WNT-T CELL; β-Catenin; SAPK\_JNK; AMPK;

Cell Cycle G1S;Cell Cycle G2M DNA;

MAPK\_ERK\_Growth;MAPK\_G\_Protein; PI3K/Akt; Protein\_Acetylation

**Background:** tumor protein p53(TP53) Homo sapiens This gene encodes a tumor suppressor

protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate

promoters result in multiple transcript variants and isoforms. Additional isoforms

have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). [provided by RefSeq, Feb 2013],

**Function:** cofactor:Binds 1 zinc ion per subunit.,disease:Defects in TP53 are a cause of

choroid plexus papilloma [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood., disease: Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any

tumor before 45 years a

Subcellular Location :

Cytoplasm . Nucleus . Nucleus, PML body . Endoplasmic reticulum .

Mitochondrion matrix. Cytoplasm, cytoskeleton, microtubule organizing center,


centrosome . Recruited into PML bodies together with CHEK2

(PubMed:12810724). Translocates to mitochondria upon oxidative stress (PubMed:22726440). Translocates to mitochondria in response to mitomycin C treatment (PubMed:27323408). .; [Isoform 1]: Nucleus . Cytoplasm. Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.; [Isoform 2]: Nucleus. Cytoplasm. Localized mainly in the nucleus with minor staining in the cytoplasm.; [Isoform 3]: Nucleus. Cytoplasm. Localized in the nucleus in most cells but found in the cytoplasm in some cells.; [Isoform 4]: Nucleus. Cytoplasm. Predominantly nuclear but translocates to the cy


## **Expression:**

Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.


## **Products Images**




Western Blot analysis of various cells using Phospho-p53 (S6) Polyclonal Antibody diluted at 1:2000



Enzyme-Linked Immunosorbent Assay (Phospho-ELISA) for Immunogen Phosphopeptide (Phospho-left) and Non-Phosphopeptide (Phospho-right), using p53 (Phospho-Ser6) Antibody



Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using p53 (Phospho-Ser6) Antibody. The picture on the right is blocked with the phospho peptide.



Western blot analysis of lysates from COS7 cells treated with H2O2 100uM 30', using p53 (Phospho-Ser6) Antibody. The lane on the right is blocked with the phospho peptide.